| Bioactivity | CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity[1]. |
| Invitro | CXCL9(74-103) (0.3-3 μM; 3-4 days) 在 HMVECs 中减少生长因子诱导的内皮细胞增殖、迁移、(0.3-3 μM; 15 min) 粘附和球状体萌芽。CXCL9(74-103) (0.3-3 μM; 24 h) 在 HMVECs 中没有细胞毒性[1]。CXCL9(74-103) (3 μM) 通过减少 VEGF165 与 HS 的结合以及直接与 FGF-2 结合来干扰生长因子信号，并依靠细胞表面 HS 与内皮细胞结合从而发挥其抗血管生成活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CXCL9(74-103) 相关抗体: |
| In Vivo | CXCL9(74-103) (皮下植入含有 400 µg/100 µL 的渗透泵) 在 C57BL/6 小鼠中能够显著减少 FGF-2 诱导的基质胶栓塞血管生成。CXCL9(74-103) (施用 10 μL 浓度为 100μg/mL 的滴剂,一天一次连续4天) 在角膜烧灼实验的 C57BL/6 小鼠中减少角膜热损伤的病理性血管生长。CXCL9(74-103) (皮下植入含有 800 µg/100 µL 的渗透泵，在两周内持续给药) 在 MDA-MB-231 乳腺癌 SCID 小鼠中减弱肿瘤血管生成。此外，CXCL9(74-103) 还减少了糖尿病大鼠视网膜的血管渗漏，具有抗血管生成作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Sequence | Lys-Lys-Lys-Gln-Lys-Asn-Gly-Lys-Lys-His-Gln-Lys-Lys-Lys-Val-Leu-Lys-Val-Arg-Lys-Ser-Gln-Arg-Ser-Arg-Gln-Lys-Lys-Thr-Thr |
| Shortening | KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT |
| Formula | C158H295N59O40 |
| Molar Mass | 3661.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. De Zutter A, et al. The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors. Cancers (Basel). 2021;13(20):5090. Published 2021 Oct 12. |